FDA orders reduction in sleeping pill dosages
WASHINGTON — The Food and Drug Administration is requiring makers of Ambien and similar sleeping pills to lower the dosage of their drugs, based on studies suggesting patients face a higher risk of injury because of morning drowsiness.
The agency said Thursday that new research shows that the drugs remain in the bloodstream at levels high enough to interfere with alertness and coordination, which increases the risk of car accidents.
Regulators are ordering drug manufacturers to cut the dose of the medications in half for women, who process the drug more slowly. Doses will be lowered from 10 milligrams to 5 milligrams for regular products, and 12.5 milligrams to 6.25 milligrams for extended-release.
The FDA is recommending that manufacturers apply these lower doses to men as well.
The new doses apply to all insomnia treatments containing the drug zolpidem, which is sold under brands including Ambien, Edluar, Zolpimist and in generic forms. It is the most widely prescribed sleeping aid prescribed in the nation. The changes don't affect other medicines like Lunesta and Sonata, which use different drugs.
“All sleep drugs have the potential to cause this, so health professionals should prescribe — and patients should take — the lowest dose that is capable of preventing insomnia,” said Dr. Ellis Unger, a director in FDA's Office of Drug Evaluation.
Show commenting policy
TribLive commenting policy
- Buffet: Berkshire’s built to last
- Most young Republicans back legal marijuana
- Huge, ancient quasar could alter theories on black holes
- Florida fisherman’s high court win spurs call for legal reform
- Paul edges Walker in CPAC straw poll
- Perceived slights have some New Yorkers longing for Pennsylvania
- Monarch butterflies find milkweed supply dwindles
- Mo. gunman kills 7, self, in rampage
- Congress approves 1-week funding measure for Homeland Security
- Gene making human brains bigger found
- Israeli Prime Minister Netanyahu rejects Jewish House Democrats’ invitation